Cambio de paradigma en el EGFR mutado: desde las primeras mutaciones a las de resistencia - page 24

Feasibility of re-biopsy in NSCLC

•

Feasible in 70% of cases

•

Need for determinations in blood

Bosc C, et al. Target Oncol 2015; 15:247-253. Chouaid C, et al. Lung Cancer 2014; 86:170-173

SEO Version

Warning.

You are currently viewing the SEO version of !text.
It has a number of design and functionality limitations.

We recommend viewing the Flash version or the basic HTML version of this publication.

1...,14,15,16,17,18,19,20,21,22,23 25,26,27,28,29,30,31,32,33,34,...35